Sign Up to like & get
recommendations!
0
Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.am2018-2701
Abstract: Although the combination of trastuzumab with cisplatin and fluoropyrimidine is standard therapy for metastatic HER2-positive gastric cancers, predictive biomarkers for this therapy need to be further refined. Given the multifactorial nature of clinical trastuzumab resistance,…
read more here.
Keywords:
biopsy;
gastric cancers;
resistant tumors;
alterations apoptotic ... See more keywords